01.

Selective TGF-β2 ASO

• The least side effects in TGF-β2 KO mice compared to other ligands KO mice
• No toxicity related to TGF-β signal observed in the Trabedersen clinical trials

02.

Tissue restricted small molecule ALK5 inhibitor

• Elimination of on-target toxicity (e.g. Cardiotoxicity) by local action on target organs
• Developable for various indications such as Idiopathic Pulmonary Fibrosis (IPF), Fibro-stenotic disease, etc.